VBIO trade update - more gains today
Published: Fri, 06/22/18
 Good morning, VBIO is continuing to run just as we thought it might. It hit $1.83 this morning, for over 7% gains which means it has gained 23% from our alert yesterday. It is anyone's guess what happens from here, but I am going to keep watching for dip buying opportunities. I would urge you to keep watching and looking for opportunities as well. All the best. SmallCapMomo.com -------------------------------------------------------------------------------- Traders and Investors, We've got an exciting new trade idea for you today, one that just released some major news yesterday and has a great looking chart to boot. Prodrugs are medications or compounds that, after administration, are converted within the body into a pharmacologically active drug, which may already have a long history of clinical investigation and use. Because the reference drug already has independent verification of its safety and efficacy, some prodrugs may be approved rapidly through demonstrating similar bioavailability or bioequivalence. At the same time, a prodrug can be far more marketable due to its ability to eliminate unwanted side effects or undesirable commercial aspects. In our case, targeted delivery could enable oral drug formulations of cannabinoids that provide therapeutic benefits while reducing or avoiding the systemic delivery of THC into the bloodstream. A classic prodrug example is Aspirin, acetylsalicylic acid, which was first made by Felix Hoffmann at Bayer in 1897 and is a synthetic prodrug of salicylic acid. As of a couple years ago, there were approximately 15 prodrugs that had been classified as blockbusters, defined as having annual sales in excess of $1 billion. One of the most hotly pursued cannabinoids for pharmaceutical purposes is cannabidiol, which is non-psychotropic, and has demonstrated therapeutic effects in clinical trials for serious neurological conditions including rare seizure disorders and for alleviating symptoms of multiple sclerosis. Our prodrugs could exert the same beneficial therapeutic effects, but with notable improvements, such as a better tasting formulation that enables improved patient compliance, better oral bioavailability that provides safer and more reliable dosing, or a delayed release mechanism that enables patients using these medications to have long-lasting, overnight relief. Given that we have recently filed intellectual property applications including strong composition of matter claims for more than 20 cannabinoid prodrugs, including versions of THC, CBD, and CBDV, we have demonstrated the ability to create a proprietary prodrug of every significant cannabinoid pharmaceutical available today. You can learn more about VBIO at their website http://vitality.bio/ Despite cannabis attaining legal status within the State of California and in many other states across the U.S. for medical and recreational purposes, pharmaceutical research and development continues to be closely regulated by the DEA and the U.S. Food and Drug Administration (FDA). Vitality initially worked with the DEA to ensure adequate on-site measures are in place to prevent diversion of Schedule I controlled substances, the most regulated tier of controlled substances in the US. In addition, the California Research Advisory Panel, a part of the California Attorney General’s Office, also approved Vitality’s cannabinoid pharmaceutical development activities. Vitality Biopharma’s operations are in compliance with federal controlled substance regulations and are enabling development of a novel class of cannabinoid prodrugs that avoid psychoactivity. The Company’s lead compound VBX-100 is a proprietary prodrug of THC that is targeted to the gastro-intestinal tract, meaning it reduces or avoids entry of THC into the bloodstream or brain. VBX-100 is produced on-site using an enzymatic biosynthesis process and will be produced according to cGMP pharmaceutical standards for use within clinical trials across the United States. “Our biocatalysis and drug manufacturing capabilities have advanced rapidly over the past 18 months, and we’re excited to continue this work with oversight from DEA, the State of California, and also the FDA,” said Dr. Brandon Zipp, Director of R&D, and Scientific Co-founder of Vitality Biopharma. Robert Brooke, CEO and Co-founder of Vitality Biopharma adds that, “Our team first pioneered a novel biosynthesis process for our cannabinoid prodrugs, and now they’ve successfully scaled it in a way that could enable widespread supply for clinical trials and even commercialization. This puts us in an enviable position within our industry, and we look forward to seeing what else can be achieved in the months and year ahead.” That's not the only news coming from VBIO though. Over recent months the Company has released a steady stream of positive news to the investing community. In Conclusion... VBIO just announced some big news today and traders responded accordingly as VBIO closed up 10%. We think it has confirmed a technical bounce off long term support. Given its history of making big runs, and its 52 week high of $2.37, there could be plenty of upside left to come. Get VBIO on your screen, do your research and be ready for a new trading day. All the best. SmallCapMomo.com --------------------------------------------------------------------------------------------------------
Remember our key trading rules when trading. Capital preservation is key. Keep your stops tight, and if things don't go your way, cut your losses and look for another opportunity. Disclaimer Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. For full disclaimer click here. SmallCapMomo.com employees are not registered as an Investment Adviser in any jurisdiction whatsoever. The disclaimer is to be read and fully understood before using our site, or joining our email list. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SmallCapMomo.com strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. SmallCapMomo.com does not offer such advice or analysis, and SmallCapMomo.com further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be "forward looking statements". Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as "projects", "foresee", "expects", "will", "anticipates", "estimates", "believes", "understands", or that by statements indicating certain actions "may", "could", or "might" occur. Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, SmallCapMomo.com has relied upon information supplied by its customers, and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, SmallCapMomo.com and its owners, affiliates, subsidiaries, officers, directors, representatives and agents have not completed any due diligence or research on the companies advertised herein and disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. SmallCapMomo.com is not responsible for any claims made by the companies advertised herein. SmallCapMomo.com may receive compensation and they, its employees and/or affiliates may own stock that they have purchased in the open market either prior, during, or after the release of the companies profile which is an inherent conflict of interest in SmallCapMomo.com statements and opinions and such statements and opinions cannot be considered independent. SmallCapMomo.com reserves the right to buy and sell shares of the profiled company on the open market before, during or after the release of the company profile. In such an event, SmallCapMomo.com will not update its disclaimer to reflect any shares bought or sold on the open market during the profile coverage. SmallCapMomo.com and its management may benefit from any increase in the share price of the profiled companies and hold the right to close positions they have entered into at any given time including before or after the release of the companies profile. SmallCapMomo.com has been compensated three thousand dollars via electronic transfer from a non-affiliated third party for the profile of VBIO. SmallCapMomo.com does not accept compensation in restricted or free-trading shares for its marketing services of the company being profiled. However the third party that has compensated SmallCapMomo.com may hold free-trading shares of the company being profiled and could very well be selling shares of the company’s stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration. If SmallCapMomo.com ever does accept compensation in the form of restricted or free trading shares of the company being profiled and decides to sell these shares into the public market at any time before, during, or after the release of the companies profile our disclaimer will be updated accordingly reflecting the position of those free trading shares received as compensation for our services at the time our promotional material is released to the public, as well as information on our intention to sell these shares during the promotional period or thereafter. Text MOMO to 555888. You will receive auto-dialed text alerts from SmallCapMomo.com. No consent req'd for purchase. Msg & data rates may apply. Msg frequency varies. Reply STOP to stop, HELP for help. |
